<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874584</url>
  </required_header>
  <id_info>
    <org_study_id>20201491</org_study_id>
    <nct_id>NCT04874584</nct_id>
  </id_info>
  <brief_title>Culturally Tailored Nurse Coaching Study for Cancer Symptom Management</brief_title>
  <official_title>Utilizing a Culturally Tailored Nurse Coaching Intervention to Decrease Symptom Severity and Prevent Dehydration in Patients With Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oncology Nursing Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see whether or not a telephone/ text message intervention,&#xD;
      delivered by a registered nurse, is helpful in managing symptoms and can also prevent&#xD;
      dehydration caused by chemotherapy treatment when given together for patients with metastatic&#xD;
      breast, colon, lung or prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MDASI scores</measure>
    <time_frame>baseline, up to 12 weeks</time_frame>
    <description>MD Anderson Symptom Inventory (MDASI) is a 19 item scale with a score range from 0-10 per symptom question that measures symptom severity plus symptom interference combined to measure total symptom burden. The higher score indicates worsening of symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidents of dehydration</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Incidents of unscheduled medical visits for IV hydration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in Chronic Disease Self-Efficacy Scale (CDSES) scores</measure>
    <time_frame>baseline, up to 12 weeks</time_frame>
    <description>The CDSES is a 10 item scale with a score range from 0-10 per symptom question that measures perceived self-efficacy. The higher score indicates better perceived self-efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Partners in Health Scale (PIHS) scores</measure>
    <time_frame>baseline, up to 12 weeks</time_frame>
    <description>The PIHS is a 12 item scale with a score range from 0-8 per question that measures symptoms self-management. The higher score indicates better symptom self-management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of completed call or text message</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Feasibility will be reported as a percentage of completed calls or text messages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FACT-B Scores</measure>
    <time_frame>baseline, up to 12 weeks</time_frame>
    <description>Health Related Quality of Life (HRQoL) will be measured by the Functional Assessment of Cancer Therapy -Breast (FACT-B). FACT-B has a total scoring of 0-148 with the higher scoring indicating better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FACT-P Scores</measure>
    <time_frame>baseline, up to 12 weeks</time_frame>
    <description>Health Related Quality of Life (HRQoL) will be measured by the Functional Assessment of Cancer Therapy -Prostate (FACT-P). FACT-P has a total scoring of 0-156 with the higher scoring indicating better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FACT-C Scores</measure>
    <time_frame>baseline, up to 12 weeks</time_frame>
    <description>Health Related Quality of Life (HRQoL) will be measured by the Functional Assessment of Cancer Therapy -Colon (FACT-C). FACT-C has a total scoring of 0-144 with the higher scoring indicating better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FACT-LC Scores</measure>
    <time_frame>baseline, up to 12 weeks</time_frame>
    <description>Health Related Quality of Life (HRQoL) will be measured by the Functional Assessment of Cancer Therapy -Lung Cancer (FACT-LC). FACT-LC has a total scoring of 0-144 with the higher scoring indicating better HRQoL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Dehydration</condition>
  <condition>Symptom Cluster</condition>
  <condition>Quality of Life</condition>
  <condition>Self Efficacy</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>CTNSM Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Culturally Tailored Nurse Symptom Management group (CTNSM) - participants in the CTNSM group will receive one in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message during the first 12 weeks of standard of care chemotherapy. In addition, participants can receive standard of care chemotherapy education.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (control) Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the control group will only be receiving the standard of care chemotherapy education.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CTNSM</intervention_name>
    <description>The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .</description>
    <arm_group_label>CTNSM Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard of Care Chemotherapy Education</intervention_name>
    <description>Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.</description>
    <arm_group_label>CTNSM Group</arm_group_label>
    <arm_group_label>Standard of Care (control) Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eligible for Chemotherapy for the first time (Previous &amp; Ongoing hormonal only&#xD;
             treatment allowed OR Neoadjuvant &amp; Adjuvant chemotherapy regimens with 2+ drugs&#xD;
             allowed)&#xD;
&#xD;
          2. &gt; 18 years old&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.&#xD;
&#xD;
          4. There are no life expectancy restrictions&#xD;
&#xD;
          5. Women of child-bearing potential are allowed in the study as long as they are eligible&#xD;
             for the chemotherapy treatment.&#xD;
&#xD;
          6. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients on immunotherapy only will be excluded&#xD;
&#xD;
          2. Previous chemotherapy&#xD;
&#xD;
          3. Under 18 years old&#xD;
&#xD;
          4. Medically Diagnosed with a Cognitive Impairment. Rationale for excluding people with&#xD;
             cognitive impairment is that they would not be able to fully participate in the&#xD;
             self-management care aspects of the intervention via the telephone, nor provide&#xD;
             informed consent.&#xD;
&#xD;
          5. No access to a telephone&#xD;
&#xD;
          6. Blind or Deaf; If subject is Hearing-impaired or illiterate, then the subject may have&#xD;
             a family member participate as a telecommunication surrogate with them in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha Solle, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tracy a Ruegg, PhD</last_name>
    <phone>3052439825</phone>
    <email>tar98@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Ctr.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy A Ruegg, PhD</last_name>
      <phone>305-243-9825</phone>
      <email>tar98@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Natasha Solle, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/33600392/</url>
    <description>Nurse-Delivered Telephone Intervention to Reduce Oral Mucositis and Prevent Dehydration</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Natasha Solle, PhD, RN</investigator_full_name>
    <investigator_title>assistant research professor</investigator_title>
  </responsible_party>
  <keyword>symptom self-management</keyword>
  <keyword>symptom severity</keyword>
  <keyword>emotional support</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydration</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

